Patents Examined by Paula K. Hutzell
  • Human galactosyltransferases
    Patent number: 5955282
    Abstract: The invention provides human galactosyltransferases (HUGA) and polynucleotides which identify and encode HUGA. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HUGA.
    Type: Grant
    Filed: April 3, 1998
    Date of Patent: September 21, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Karl J. Guegler, Neil C. Corley, Purvi Shah, Chandra Patterson
  • BH3 interacting domain death agonist
    Patent number: 5955593
    Abstract: A novel death agonist, BID, which is related to the BCL-2 family of apoptosis regulating proteins only in the conserved BH3 domain, is provided along with encoding polynucleotides. BID polypeptides and derivatives thereof are useful in modulating apoptosis. Polynucleotides encoding BID polypeptides and derivatives thereof are useful as templates for recombinantly expressing BID polypeptides, as probes for detecting endogenously expressed BID polynucleotides, and in gene therapy for treating or preventing disease. Methods for modulating inappropriate expression of BID using BID antisense molecules or anti-BID antibodies are also provided. In addition, screening assays for identifying agents which modulate binding between BID and other BCL-2 family members are provided.
    Type: Grant
    Filed: September 9, 1996
    Date of Patent: September 21, 1999
    Assignee: Washington University
    Inventor: Stanley J. Korsmeyer
  • Induction of CTLs specific for natural antigens by cross priming immunization
    Patent number: 5951975
    Abstract: The present invention relates to prophylactic and therapeutic methods of anti-tumor immunization. These methods are based on cross-priming a mammalian host to natural MHC class I restricted tumor antigens with an artificial tumor antigen. A primary tumor is resected from the patient and a population of tumor cells are cultured in vitro. These cultured tumor cells are loaded with an artificial target antigen. The loaded tumor cells are inactivated and introduced into the patient either simultaneous or subsequent to a direct immunization of the patient with the same or substantially the same artificial target antigen. This method of coupled host immunization promotes a tumor specific cytotoxic T lymphocyte (CTL) immune response against multiple, undefined natural tumor antigens expressed on the unmodified tumor cell surface.
    Type: Grant
    Filed: June 28, 1996
    Date of Patent: September 14, 1999
    Assignees: University of Pittsburgh, Dana-Farber Cancer Institute
    Inventors: Louis D. Falo, Jr., Kenneth L. Rock
  • Opsonin-enhanced cells, and methods of modulating an immune response to an antigen
    Patent number: 5951976
    Abstract: Disclosed are methods and compositions wherein opsonin-enhanced cells, that is, cells which have been 1) modified so as to express an opsonin from a recombinant nucleic acid, 2) modified so as to express higher levels of an endogenous opsonin, or 3) mixed with an exogenous opsonin, when administered to a subject, modulate the immune response in the recipient to a selected antigen or antigens contained in or attached to the cells.
    Type: Grant
    Filed: March 27, 1997
    Date of Patent: September 14, 1999
    Assignee: Whitenead Institute for Biomedical Research
    Inventor: Andrew H. Segal
  • Antibody that binds to cluster w-4 polypeptide of human small cell lung carcinoma cells
    Patent number: 5952471
    Abstract: Binding agents, such as antibodies, are described which selectively bind to the cluster-w4 polypeptide of human small cell lung carcinoma cells at a site located at and around valine-57 of the cluster-w4 polypeptide. The binding agents, either alone or linked to a reporter or effector molecule are of use in the diagnosis or treatment of human small cell lung carcinoma. Also described are peptides (A).sub.m -(T).sub.n -(T).sub.o -(K).sub.p -V-(A).sub.q -(G).sub.r -(G).sub.s -(A).sub.t -(L).sub.u having at least one of the core structures K-V-A, T-K-V, or V-A-G for use in the identification and/or preparation of binding agents according to the invention, as diagnostic reagents, or as immunostimulants.
    Type: Grant
    Filed: February 3, 1997
    Date of Patent: September 14, 1999
    Assignee: Celltech Therapeutics Limited
    Inventor: Alastair David Griffiths Lawson
  • Anti-fibroblast growth factor-8 monoclonal antibody
    Patent number: 5952472
    Abstract: Described is a monoclonal antibody capable of specifically binding to fibroblast growth factor-8 (FGF-8) which is related to growth factors of hormone-dependent tumor cells such as prostatic cancer and breast cancer, and inhibits the FGF-8 activity. The monoclonal antibody is useful in analyzing the role and biological function of FGF-8 in hormone-dependent tumor cells such as prostatic cancer and breast cancer and can be beneficial in the treatment of these cancers.
    Type: Grant
    Filed: April 3, 1997
    Date of Patent: September 14, 1999
    Assignee: Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Nobuo Hanai, Motoo Yamasaki, Akiko Furuya, Akira Tanaka
  • Synthesis of estrogen-purine base and estrogen-mercapturate adducts and development of fluorescent probes and monoclonal antibodies to assay those adducts
    Patent number: 5952183
    Abstract: Estrogen-nucleoside, estrogen-guanine and estrogen-mercapturate adducts are potential biomarkers for determining susceptibility of animals to a number of estrogen related cancers. These adducts may be used as biomarkers for determining risk of estrogen-induced cancers. A linker chemistry has been devised to couple these adducts to protein for production of immunogens, required for production of specific monoclonal antibodies.
    Type: Grant
    Filed: April 15, 1998
    Date of Patent: September 14, 1999
    Inventors: Ercole L. Cavalieri, George P. Casale, Eleanor G. Rogan, Douglas E. Stack
  • Human arsenite-resistance protein
    Patent number: 5952479
    Abstract: The invention provides a human arsenite-resistance protein (NITE) and polynucleotides which identify and encode NITE. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of NITE.
    Type: Grant
    Filed: May 7, 1998
    Date of Patent: September 14, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Neil C. Corley, Chandra Patterson
  • Labelled peptide compounds
    Patent number: 5952464
    Abstract: The invention relates to a labelled peptide compound, wherein the peptide has a selective neurotensin receptor affinity and is represented by the general formulaR.sub.1 -(.sup.1 Pro).sub.n -.sup.2 Xaa-.sup.3 Xbb-.sup.4 Xcc-.sup.5 Xdd-.sup.6 Xee-.sup.7 Leu-OH (SEQ ID NO:2) (I)wherein:R.sub.1 is a (C.sub.1 -C.sub.3)alkanoyl group, an arylcarbonyl group, an aryl-(C.sub.1 -C.sub.3)alkanoyl group, or a chelating group attached by an amide bond or through a spacing group to the peptide molecule;Xaa and Xbb are each individually Arg or Lys;Xcc is an unsubstituted or substituted cyclic amino acid, preferably selected from Pro and Hyp;Xdd is Tyr, Trp or Phe;Xee is Leu, Ile or t.-butylalanine; andn is 0 or 1;and wherein said peptide is labelled with (a) a metal isotope, or (b) with a radioactive halogen isotope; on the understanding that:(i) if the label is a metal isotope, R.sub.
    Type: Grant
    Filed: July 21, 1997
    Date of Patent: September 14, 1999
    Assignee: Mallinckrodt Inc.
    Inventors: John Mertens, Dirk Tourwe, Marc Ceusters
  • Human cytosolic isocitrate dehydrogenase
    Patent number: 5952177
    Abstract: The invention provides a human cytosolic isocitrate dehydrogenase (HCID) and polynucleotides which identify and encode HCID. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating disorders associated with expression of HCID.
    Type: Grant
    Filed: December 3, 1997
    Date of Patent: September 14, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Preeti Lal, Neil C. Corley, Janice Au-Young
  • Method for inducing immunological tolerance, immunological tolerance inducing food kit, and immunological tolerance inducer kit
    Patent number: 5951984
    Abstract: A method for inducing immunological tolerance in mammals which comprises feeding an immunogen to a mammal, wherein the mammal is not allowed to ingest a fat-soluble component or a fat-soluble component-containing substance simultaneous with ingestion of the immunogen, and an immunological tolerance including food kit and an immunological tolerance inducer kit which comprises an immunogen-containing preparation containing no fat-soluble component and an immunogen-free preparation containing no fat-soluble component. According to this invention, immunological tolerance can be induced effectively.
    Type: Grant
    Filed: January 22, 1997
    Date of Patent: September 14, 1999
    Assignee: Meiji Milk Products Company, Limited
    Inventors: Tetsuo Kaneko, Yuka Nozaki, Yukiko Ishiguro, Tamotsu Kuwata
  • Modulators of BRCA1 activity
    Patent number: 5948643
    Abstract: Compositions of matter consisting of a family of related nucleotide sequences that encode proteins, termed BRCA1 Modulator Proteins, that bind to the tumor suppressor gene product BRCA1, and methods of using the nucleotide sequences and the proteins encoded thereby, to diagnose and/or treat disease where the BRCA1 Modulator Proteins have an apparent molecular weight of 45-97 kdaltons and are characterized by having at least one leucine zipper domain, and optionally a zinc finger domain.
    Type: Grant
    Filed: August 13, 1997
    Date of Patent: September 7, 1999
    Assignee: Onyx Pharmaceuticals, Inc.
    Inventors: Bonnee Rubinfeld, Paul G. Polakis, Carol Lingenfelter, Terilyn T. Vuong
  • Mammalian additional sex combs (mammalian Asx) acts as a tumor suppressor
    Patent number: 5948640
    Abstract: Mammalian Asx gene and amino acid sequences encoded by the mammalian Asx gene, are described. The mammalian Asx gene and gene products are useful for diagnostic and therapeutic applications in proliferative and developmental disorders. Modulators of mammalian Asx can be identified using the disclosed genes. The modulators can be used in the context of cancer therapy or a treatment of a developmental disorder. Asx is also useful for inducing differentiation in a population of progenitor cells.
    Type: Grant
    Filed: May 8, 1997
    Date of Patent: September 7, 1999
    Assignee: Chiron Corporation
    Inventor: Filippo M. Randazzo
  • Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
    Patent number: 5948646
    Abstract: The present invention relates to methods for preparing immunogenic, prophylactically and therapeutically effective complexes of heat shock proteins noncovalently associated with antigenic peptides of cancer cells. The claimed methods comprise the constructing of a cDNA library from cancer or preneoplastic cell RNA, expressing the cDNA library in an appropriate host cell, and recovering the immunogenic complexes from the cells. Large amounts of such immunogenic complexes can be obtained by large-scale culturing of host cells containing the cDNA library. The complexes can be used as a vaccine to elicit specific immune responses against cancer or preneoplastic cells, and to treat or prevent cancer.
    Type: Grant
    Filed: December 11, 1997
    Date of Patent: September 7, 1999
    Assignee: Fordham University
    Inventor: Pramod K. Srivastava
  • Nucleic acids encoding two human heat shock protein homologs, and methods of detection thereof
    Patent number: 5945287
    Abstract: The invention provides two human heat shock protein homologs (HSPHH-1, HSPHH-2) and polynucleotides which identify and encode HSPHH-1 and HSPHH-2. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of HSPHH-1 and HSPHH-2.
    Type: Grant
    Filed: November 19, 1997
    Date of Patent: August 31, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Purvi Shah, Neil C. Corley, Preeti Lal
  • Method for distinguishing viable, early apoptotic, late apoptotic, and necrotic cells
    Patent number: 5945291
    Abstract: The present invention provides a method for distinguishing between viable, early apoptotic, late apoptotic and necrotic cells utilizing multi-color immunofluorescence.
    Type: Grant
    Filed: November 10, 1997
    Date of Patent: August 31, 1999
    Assignee: Coulter International Corp.
    Inventors: Wade E. Bolton, Steven K. Koester
  • Method of detecting and treating cancer
    Patent number: 5942402
    Abstract: The present invention provides a new method for diagnosing and treating cancers or BPH. Further provided are therapeutic agents and pharmaceutical compositions for treating cancers and BPH.
    Type: Grant
    Filed: January 7, 1999
    Date of Patent: August 24, 1999
    Assignee: SmithKline Beecham Corporation
    Inventors: Carl J. Schmidt, Frank Tobin, Francis E. Wilkinson
  • Nematode vaccine
    Patent number: 5942413
    Abstract: Disclosed is a substantially purified antigen derived from a first species of parasitic nematodes, which antigen is capable of providing protection to a host from parasitism infestation by a second nematode species, which may be the same as or different from the first nematode species, following vaccination of the host with the antigen, characterized in that the antigen is proteinaceous, has a pI between 3.8 and 4.4, can be bound by lentil lectin and Helix promatia and has a molecular weight of approximately 45 kD as determined by SDS-PAGE.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: August 24, 1999
    Assignees: Biotech Australia PTY Limited, Commonwealth Scientific and Industrial Research Organization
    Inventors: Phillip John Sharp, Barry Maxwell Wagland, Gary Stewart Cobon
  • Stimulation of gene expression and synthesis of heat shock protein 72/73 (HSP 70)
    Patent number: 5942494
    Abstract: This invention provides a method for increasing the level of heat shock protein in a cell which comprises contacting the cell with an effective amount of N-acetyl-leucyl-leucyl-norleucinal, so as to thereby increase the level of heat shock protein in the cell. This invention further provides a protein characterized by increased levels of the protein in a cell in response to contacting the cell with an effective amount of N-acetyl-leucyl-leucyl-norleucinal. This invention also provides a method for increasing the binding of apoprotein B100 to a heat shock protein in a cell. This invention provides a method of preserving an organ ex vivo, which comprises contacting the organ with an effective amount of N-acetyl-leucyl-leucyl-norleucinal. This invention also provides a method of preserving an organ in vivo, which comprises contacting the organ with an effective amount of N-acetyl-leucyl-leucyl-norleucinal.
    Type: Grant
    Filed: September 30, 1996
    Date of Patent: August 24, 1999
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Henry N. Ginsberg, Xujun Wu, Mingyue Zhou
  • Viral receptor protein
    Patent number: 5942606
    Abstract: The invention provides a human viral receptor protein (ACVRP) and polynucleotides which identify and encode ACVRP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of ACVRP.
    Type: Grant
    Filed: November 24, 1997
    Date of Patent: August 24, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Preeti Lal, Neil C. Corley